Compounds with ALK inhibitory activity and preparation method and use thereof
The present application relates to the technical field of pharmaceutical chemistry, and particularly relates to compounds with ALK inhibitory activity and preparation method and use thereof. The compounds with ALK inhibitory activity provided by the present application are ALK inhibitors for treating diseases responsive to the inhibition of ALK kinase, can be used for treating ALK-positive diseases, such as tumors and cancers, and have broad application prospects.
1 . A compound shown in formula (I) or a pharmaceutically acceptable salt thereof:
wherein, R 1 is selected from hydrogen, substituted or unsubstituted C1-C4 alkyl, C3-C6 cycloalkyl, substituted or unsubstituted aryl or heterocyclic aryl, and halogen;
R 2 is selected from hydrogen, substituted or unsubstituted C1-C4 alkyl, cyano, and halogen; the substituent of C1-C4 alkyl is selected from C3-C6 cycloalkyl, halogen, and cyano;
R 3 is selected from heterocyclic aryl, aryl, and substituted or unsubstituted 5-7 membered heterocycle, wherein the 5-7 membered heterocycle contains 1-3 heteroatoms that are each independently selected from N, P, O, and S;
R 4 and R 5 are each independently selected from hydrogen, substituted or unsubstituted saturated C1-C4 alkyl, and substituted or unsubstituted unsaturated C1-C4 alkyl.
2 . The compound or a pharmaceutically acceptable salt thereof according to claim 1 ,
wherein,
R 1 is selected from hydrogen, substituted or unsubstituted C1-C4 alkyl, C3-C6 cycloalkyl;
R 2 is selected from hydrogen, unsubstituted C1-C4 alkyl, cyano, and halogen;
R 3 is selected from substituted or unsubstituted 5-7 membered heterocycle, wherein the 5-7 membered heterocycle contains 1-3 heteroatoms that are each independently selected from N, P, O, and S;
R 4 and R 5 are each independently selected from hydrogen, and unsubstituted saturated C1-C4 alkyl.
3 . The compound or a pharmaceutically acceptable salt thereof according to claim 2 ,
wherein,
R 1 is selected from hydrogen, methyl, ethyl, propyl,
R 2 is selected from methyl, ethyl, propyl, cyano, Cl, Br, and F;
R 3 is selected from substituted or unsubstituted 6-membered heterocycle, wherein the 6-membered heterocycle contains 1-3 heteroatoms of N;
R 4 and R 5 are each independently selected from hydrogen, methyl, ethyl, and propyl.
4 . The compound or a pharmaceutically acceptable salt thereof according to claim 3 ,
wherein,
R 1 is selected from hydrogen, methyl, and
R 2 is selected from methyl, ethyl, cyano, Cl, Br and F;
R 3 is selected from
R 6 , R 7 , and R 8 are each independently selected from hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycle, cyano, halogen, and nitrogen-containing alkyl; the 4-7 membered heterocycle contains 1-3 heteroatoms that are each independently selected from N, P, O, and S;
R 4 and R 5 are each independently selected from methyl.
5 . The compound or a pharmaceutically acceptable salt thereof according to claim 4 ,
wherein,
R 6 , R 7 , and R 8 are each independently selected from hydrogen, methyl, ethyl, cyano, dimethylamino, diethylamido,
6 . The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein,
R 1 is selected from hydrogen and
R 2 is selected from ethyl, cyano, and Cl;
R 3 is selected from
7 . The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein, the compound shown in formula (I) is selected from:
8 . A method for preparing the compound or a pharmaceutically acceptable salt thereof according to claim 7 , comprising at least the following steps: adding a carbonate into a solution of a compound of formula (II) in methanol, and stirring the mixture to conduct a reaction; wherein the compound of formula (II) is represented by the following formula:
wherein, R′ 2 is selected from ethyl, cyano, Cl, Br, and F;
R′ 3 is selected from
R 6 , R 7 , and R 8 are each independently selected from hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycle, cyano, halogen, and nitrogen-containing alkyl; the 4-7 membered heterocycle contains 1-3 heteroatoms that are each independently selected from N, P, O, and S;
R′ 4 represents hydrogen or unsubstituted saturated C1-C4 alkyl;
R′ 5 represents hydrogen or unsubstituted saturated C1-C4 alkyl.
9 . A method for preparing the compound or a pharmaceutically acceptable salt thereof according to claim 7 , comprising at least the following steps: adding a compound of formula (III) and a carbonate into acetonitrile and methanol, and stirring the mixture to conduct a reaction, wherein the compound of formula (III) is represented by the following formula:
R″ 3 is selected from
R 4 and R″ 4 represent the same group;
R 5 and R″ 5 represent the same group.
10 . A method for preparing the compound or a pharmaceutically acceptable salt thereof according to claim 7 , comprising at least the following steps: adding tetrabutylammonium fluoride into a solution of a compound of formula (IV) in tetrahydrofuran, and stirring the mixture to conduct a reaction, wherein the the compound of formula (IV) is represented by the following formula:
R′″ 3 is selected from
11 . A method for preparing the compound or a pharmaceutically acceptable salt thereof according to claim 7 , comprising at least the following steps: adding tripotassium phosphate, 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl, and tris(dibenzylideneacetone) dipalladium into a solution of a compound of formula (V) and alkyl an alkyne in acetonitrile, and stirring the mixture to conduct a reaction in an inert atmosphere; wherein the compound of formula formula (V) is represented by the following formula:
the alkyl alkyne is one selected from the group consisting of ethynyl cyclopropane, propyne, ethynyl cyclobutane, and butyne.
12 . A pharmaceutical composition, comprising a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 , and a medicinal carrier or excipient.
13 . A method for inhibiting ALK activity in a subject in need thereof, which comprises a step of administrating a therapeutically effective amount of the pharmaceutical composition according to claim 12 to the subject.
14 . A method for treating ALK-positive tumors or cancers in a subject in need thereof, which comprises a step of administrating a therapeutically effective amount of the pharmaceutical composition according to claim 12 to the subject.